NEW YORK, March 17, 2017 /PRNewswire/ --
This morning, Stock-Callers.com reviews select Biotech equities, namely:VIVUS Inc. (NASDAQ: VVUS), Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), Cymabay Therapeutics Inc. (NASDAQ: CBAY), and Omeros Corp. (NASDAQ: OMER). According to a report on ETFtrends.com, market observers are growing more bullish on the sector as a
Mountain View, California headquartered VIVUS Inc.'s stock finished Thursday's session 0.90% lower at $1.10, with a total trading volume of 498,547 shares. Shares of the Company, which develops and commercializes therapies to address unmet medical needs in the US and the European Union, are trading below their 50-day moving average by 3.49%. The stock has a Relative Strength Index (RSI) of 46.94.
On March 08th, 2017, VIVUS announced that net income for Q4 2016 and full year 2016 was $56.6 million and $23.3 million, respectively, compared to a net loss of $12.2 million and $93.1 million in 2015, respectively. Cash, cash equivalents, and available-for-sale securities were $269.5 million at December 31st, 2016. Your complete research report on VVUS can be retrieved for free at:
Shares in Novato, California headquartered Ultragenyx Pharmaceutical Inc. declined 2.89%, ending yesterday's session at $85.57, with a total trading volume of 362,146 shares. The stock has gained 12.23% in the past month, 23.10% in the previous three months, and 21.70% on an YTD basis. The Company's shares are trading 11.64% above their 50-day moving average and 24.27% above their 200-day moving average. Moreover, shares of Ultragenyx Pharma, which focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the US, have an RSI of 59.25.
On February 16th, 2017, Ultragenyx reported a net loss of $71.3 million, or $1.75 per share, basic and diluted for Q4 2016, compared with a net loss for Q4 2015 of $55.2 million, or $1.42 per share, basic and diluted. For the year ended December 31st, 2016, net loss was $245.9 million, or $6.21 per share, basic and diluted, compared with a net loss for the same period in 2015 of $145.6 million, or $3.96 per share, basic and diluted. This reflected cash used in operations of $161.0 million for the full year 2016 compared to $106.0 million for the same period in 2015. Cash, cash equivalents, and investments were $498.1 million as of December 31st, 2016. A free report on RARE is just a click away at:
On Thursday, Newark, California-based Cymabay Therapeutics Inc.'s stock closed the day flat at $4.25, with a total trading volume of 428,608 shares. The Company's shares have surged 72.76% in the last one month, 157.58% in the previous three months, and 145.66% on an YTD basis. The stock is trading 64.66% and 107.43% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Cymabay Therapeutics, which focuses on developing therapies to treat metabolic diseases, have an RSI of 77.93.
On March 16th, 2017, CymaBay Therapeutics announced that it will host a conference call and live audio webcast on March 23rd, 2017 at 4:30 p.m. ET to discuss Q4 and full year 2016 financial results and provide a business update. Sign up for your complimentary research report on CBAY at:
Shares in Seattle, Washington-based Omeros Corp. ended the day 1.31% higher at $11.60. A total volume of 454,013 shares was traded, which was above their three months average volume of 373,330 shares. The stock has gained 3.48% in the last one month, 14.29% in the previous three months, and 16.94% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 10.06% and 7.82%, respectively. Furthermore, shares of Omeros, which discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system, have an RSI of 56.53.
On March 01st, 2017, Omeros announced additional positive data from the ongoing Phase-2 clinical trial evaluating OMS721 in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HCT-TMA). The Phase-2 uncontrolled clinical trial is ongoing in patients with one of three types of TMA, including HCT-TMA. To be eligible for enrollment, HCT-TMA patients are required to be adults with post-transplant TMA persisting at least two weeks following calcineurin inhibitor modification. Register for free on Stock-Callers.com and download the latest research report on OMER at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!